Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer: Is Escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?

Strahlentherapie und Onkologie

Volumn 182, Issue 3, 2006, Pages 135-141

  Galalae, Razvan M ^a   Martinez, Alvaro ^b   Nuernberg, Nils ^c   Edmundson, Gregory ^b   Gustafson, Gary ^b   Gonzalez, Jose ^b   Kimming, Bernhard ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c Stadtisches Krankenhaus Kiel   (Germany)

Author keywords

Conformal HDR brachytherapy; Hormone na ve; Local dose escalation; Prostate cancer

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; TREATMENT INDICATION; TREATMENT OUTCOME; BLOOD; METHODOLOGY; MORTALITY; PROSTATE TUMOR; RADIATION DOSE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL;

ACTUARIAL ANALYSIS; BRACHYTHERAPY; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33646099847     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-006-1448-5     Document Type: Article

References (21)

1. Aebersold DM, Isaak B, Thalmann G, et al. Applicability and dosimetric impact of ultrasound-based preplanning in high-dose rate brachytherapy of prostate cancer. Strahlenther Onkol 2004;180:351-7.
2. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-101.
3. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show a high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;52:6-13.
4. Cox DR. Regression models and life table. J R Stat Soc 1971;34:187-220.
5. Edwards BK, Howe HL, Ries LAG, et al. Annual report to the nation on status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002;94:2766-92.
6. Fowler JF, Ritter MA, Chappell RJ, et al. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003; 56:1093-104.
7. Galalae R, Kovacs G, Schultze J, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high dose rate brachytherapy for advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002;52:81-90.
8. Galalae RM, Loch T, Riemer B, et al. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer. Strahlenther Onkol 2004;180:582-9.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:447-57.
10. Martin T, Baltas D, Kurek R, et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 2004;180:225-32.
11. Martinez A, Gonzalez J, Spencer W, et al. Conformal high dose rate brachytherapy improves biochemical control and cause-specific survival in patients with prostate cancer and poor prognostic factors. J Urol 2003;169:974-9.
12. Martinez AA, Galalae R, Gonzalez J, et al. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for prostate cancer patients treated to a high total radiation dose. J Urol 2003;170:2296-301.
13. Martinez AA, Gonzalez J, Stromberg J, et al. Conformal prostate brachytherapy: initial experience of a phase I/II dose escalating trial. Int J Radiat Oncol Biol Phys 1995;33:1019-27.
14. Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2003;53:316-27.
15. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
16. Smit WG, Helle PA, van Putten WL, et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 1990;18:23-9.
17. Van der Hage JA, Putter H, Bonnema J, et al. Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. Eur J Cancer 2003;39:2192-9.
18. Villeirs GM, Van Vaerenbergh K, Vakaet L, et al. Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer. Strahlenther Onkol 2005;181:424-30.
19. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/NO, MO) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999;44:809-19.
20. Zelefsky M, Fuks Z, Chan H, et al. Ten-year results of dose escalation with 3-dimensional conformal radiotherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2003;57;Suppl:149-50.
21. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-81.